310 likes | 1.83k Views
08/09/2012. Fibrocystic Breast Disease - Prof.S.N.Panda. 2. Fibrocystic Breast Disease (FBD). Most benign breast conditionIncidence-varying, related to ageMenstruating years-200-50% in premenopausal yearsSynonyms-Mammary dysplasia, Cystic disease, Cyclic Mastopathy, Cystic Hyperplasia. 08/
E N D
1. Fibrocystic Breast Disease Dr.Surendra Nath Panda, M.S.
Professor of Obstetrics & Gynaecology
M.K.C.G.Medical College
Berhampur, ORISSA, INDIA
2. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 2 Fibrocystic Breast Disease (FBD) Most benign breast condition
Incidence-varying, related to age
Menstruating years-20%
30-50% in premenopausal years
Synonyms-
Mammary dysplasia,
Cystic disease,
Cyclic Mastopathy,
Cystic Hyperplasia
3. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 3 Pathophysiology Hormonal basis
Oestrogen & Progesterone
Prolactin
Thyroid
Methylexanthiones
Trauma- NOT A CAUSE
4. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 4 Oestrogen & Progesterone
Oestrogen predominance over progesterone is considered causative
Serum levels of Oestrogen >
Luteal phase is shortened
Progesterone level decreased to 1/3 normal
Corp. Lut. Deficiency / Anovulation in 70%
Patients with Pre Menstrual Tension syndrome more likely to develop FBD
Women with progesterone deficiency carry a five fold risk of premenopausal breast cancer
5. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 5 Prolactin-
levels are increased in 1/3 of women with FDB
Probably due to Oestrogen dominance on pituitary
Thyroid –
Suboptimal levels sensitize mammary epithelium to Prolactin stimulation
Methylexanthiones-
Increased intake of coffee, tea, cold drinks chocolate is associated with development of FDP
6. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 6 Pathomorphology Oestrogens stimulate proliferation of connective and epithelial tissues.' The polymorphism of fibroeystic disease is documented by fibrosis, cyst formation, epithelial proliferation, and lobular-alveolar atrophy. FBD entails simultaneous progressive and regressive change. Ductular branching, intraductal epithelial proliferation(papillomatosis), lobular hyperplasia, and proliferation of intralobular connective tissue may undergo regressive changes such as. adenofibrosis, srlerosing adenosis, duct dilation, cyst formation, and calcification. Loss of parenchymal elements (ductules, alveoli) with intra-lobular and periductal fibrosis is encountered in chronic disease.
7. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 7 Cyst formation as a consequence of obstruction by stromal fibrosis and per- sisting ductular alveolar secretion, whereby material is retained, leading to dilation of terminal ducts (duct ectasia) and alveoli with cyst formation. In 20% to 40% of patients with fibroeystic dis- ease, gross cyst formation is observed.
Macrocysts (>1 em in diameter) rep- resent an advanced form of fibrocystic disease. They develop in women mainly in their forties and, depending on the degree of fluid filling and pericystic fi- brosis, appear softer or harder.
Pathomorphology
8. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 8 Histopathological sections of breast showing FBD Pathomorphology
9. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 9 Clinical Course
10. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 10 Clinical Course
11. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 11 Clinically, three phases of fibrocystic disease can be recognized-
Phase I-Moderate stromal fibrosis, beginning hardness of breast tissue and premenstrual breast tenderness
Phase II- Progressive fibrosis leading to increased hardening and tenderness, cyst formation, moderate modularity
Phase III- Pronounced fibrosis and tenderness, macrocyst formation Clinical Course
12. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 12 Diagnosis Fibroeystic disease has a history of many months to several years.
Fibroeystic disease is rare in ovulating women, multiparous women, and patients using oral contraceptives.
Breast pain (mastodynia) and/or tenderness is observed in the majority of patients.
In 40% to 60% of patients these are associated with irregular menses, dysmenorrhea, menometrorrhagia, or ovarian cysts.
13. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 13 Breast pain (mastodynia) and/or tenderness is observed in the majority of patients.
Mastodynia may start a few days or 1 to 2 weeks before menstruation; it usually eases or subsides with the onset of or during menses.
In more than half of the patients with mazoplasia, pre- menstrual breast swelling, mastodynia, and irregular menses, are observed. In approximately 20% of patients, axillary tenderness and enlarged lymph nodes are observed. Diagnosis
14. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 14 Nipple secretion-
In one third of patients with FBD, discharge is spontaneous or secretion can be expelled from the nipple. The cytological features may include amorphous material (fat, proteins), ductal cells, erythrocytes, andlor foam cells. 7he fluid is straw yellow, green- ish, or bluish. In 2-3% carcinoma is diagnosed
Bloody Nipple secretion- when present
50-60% due to intra ductal proliferation (Papilloma)
30-40% due to carcinoma ( 64% after age 50). Diagnosis
15. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 15 Mammography –
16. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 16 Mammography –
17. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 17 Ultrasonography -
Particularly useful in delineating solid from cystic breast masses.
Ultrasound of cystic masses characteristically defines a mass with a uniform outer margin demonstrating no asymmetry or unusual thickness of the wall. The central part of the mass shows no echoes, and there is posterior wall enhancement.
18. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 18 Needle aspiration biopsy –
Indicated in patients with breast mass, a lump like structure,, a hard dense area or any abnormal tissue areas, as defined by clinical examination, mammography or USG.
In patients at high risk of breast cancer, needle aspiration should be performed when the slightest suspicion arises.
In women with fibrocystic disease, ductal epithelium consists of cohesive cells with a scant rim of cytoplasm and round or oval small, slightly hyper chromatic nuclei. Connective (fibrous) tissue is usually predominant.
19. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 19 Treatment Goal-
To stop progression
To relieve pain
To reverse changes
Soften breast tissue
Indicated when-
Fibroadenoma is not increasing in size
No nipple discharge
No psychological effect Intervention indicated when-
Fibroadenoma is increasing in size
Serous / Serosanguineous / bloody discharge occurs
Patients are pshychologicaly disturbed
20. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 20 Ineffective modalities
Diet therapy-Caffeine restriction
Diuretics
Iodine containing agents
Thyroid hormone
Evening Primrose oil
Vitamin E & B6
Dihydroergotamine
Antiprolactin drugs
Analgesics Hormones-
Low Oestrogen Combined OC pills
Progestogens in the luteal phase
Antioestrogens- Tamoxifen
Androgens-Danazol
21. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 21 OC pills-
Users are protected from FBD
Progestogen potency should be high
Progestogens -
To be given in the luteal phase for 9-12 months
About 80% get relief but 40% require restart of therapy Danazol
Remains the most effective therapy
Basis- ovarian supression
Dose-200-600mg/day
22. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 22
23. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 23 Treatment Preferences of 276 Consultants (UK) – BeLieu RM,1994
24. 08/09/2012 Fibrocystic Breast Disease - Prof.S.N.Panda 24 THANK YOU